Skip to main content
Premium Trial:

Request an Annual Quote

MediSapiens to Offer Data Solutions on Microsoft Cloud

NEW YORK (GenomeWeb) – Finnish healthcare data company MediSapiens has announced it will offer its Explorer Platform on Microsoft's Azure Cloud.

To start out, the firm will offer Azure-based data curation, management, and analytics to healthcare organizations in Finland.

"Microsoft's focus on data security and regulatory compliance are perfectly matched with MediSapiens' endeavors on bringing world class genomic, clinical and biomedical big data solutions to benefit healthcare facilities and clinical research not only in Finland but globally," MediSapiens Chief Commercial Officer Marko Kuisma said in a statement. The deal means many institutions will be able to implement MediSapiens' platform on their existing IT infrastructure, he noted, adding, "Customers will be able to run heavy-duty genomic and clinical data analytics, but the data will never need to exit the customer's firewalls."

MediSapiens said it will continue to offer its solutions on its own servers, client-hosted servers, and both private and commercial cloud-based servers.

Last month, the firm joined the Canine Genomics project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.